Cortical Atrophy Related to Tumor Prosthesis in Skeletally Immature Osteosarcoma Patients. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Kim, Wanlim; Han, Ilkyu; Cho, Hwan-Seong; Kang, Seungcheol; Kim, Han-Soo
• Is Part Of: Journal of pediatric orthopaedics. Volume 38:Issue 1(2018)
• Publication Date: 2018-01
• Subjects: osteosarcoma -- cortical atrophy -- tumor prosthesis; Pediatric orthopedics -- Periodicals; 618.927
• DOI: 10.1097/BPO.0000000000000718
• Languages: English
• ISSNs: 0271-6798

Abstract

Abstract : Background: Cortical atrophy is commonly observed after prosthetic reconstruction for bone sarcomas. However, relevant literature regarding this phenomenon in skeletally immature patients is limited. Therefore, in this study, we evaluated the incidence and patterns of cortical atrophy. We then assessed its predisposing factors. Finally, we analyzed whether cortical atrophy was associated with poor prosthesis survival. Methods: We retrospectively reviewed 31 stems in 19 skeletally immature osteosarcoma patients who were treated with resection and tumor prosthesis surgery. We measured the cortical thickness using plain radiographs annually. The mean patient age was 11 years (range, 6 to 14 y) and the mean follow-up period was 10 years (range, 2 to 14 y). Results: Cortical atrophy developed in 13 stems, all within 3 years. There were 3 gross types of cortical atrophy: hourglass in 5, sharpening in 4, and shortening atrophy in 4. On multivariate analysis, stem-cortex diameter ratio of ≥0.5 and age of less than 10 years were significantly associated with cortical atrophy ( P =0.002 and P =0.019, respectively). Cortical atrophy was significantly associated with eventual prosthesis failure (9/13 in the cortical atrophy group vs. 4/18 in the nonatrophy group, P =0.035). Conclusions: Cortical atrophy is common in the skeletally immature patients with tumor prosthesis and is associated with prosthesis failure. Patients with cortical atrophy should be closely monitored for prosthesis failure and appropriately managed to prevent failures. Level of Evidence: Level IV—therapeutic study.